Suppr超能文献

发现用于性传播疾病的活性化疗药物以抑制致病性人乳头瘤病毒16型E6蛋白

Discovering Active Chemotherapeutic Agents for Sexually Transmitted Diseases to Inhibit Pathogenic HPV-16-E6 Protein.

作者信息

Vani Vemula, Alagumuthu Manikandan, Prasad Sanjay, Paul Nikita, Gajendra Nithya, Narayanaswamy Pooja, Venkataraman Pooja

机构信息

Department of Microbiology, MS Ramaiah College of Arts, Science and Commerce, Bangalore, 560054, India.

Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Chennai, 602105, India.

出版信息

Curr Drug Discov Technol. 2025;22(4):e15701638336294. doi: 10.2174/0115701638336294250109052352.

Abstract

BACKGROUND

One of the most prevalent sexually transmitted diseases (STDs) is infection with the human papillomavirus (HPV). The current treatment methods comprise employing chemotherapeutic medications or doing surgery to remove the developed tumors. A more affordable option for treating HPV-related diseases has emerged with the advent of medication-based therapy. The interaction between E6 protein and E6AP generates a p53 degradation complex in HPV-infected cells, which facilitates carcinogenesis.

OBJECTIVE

The purpose of this work is to use a virtual screening technique to find possible small molecule inhibitors against the HPV16 E6 protein.

METHODS

Compounds 5, 7, and 10 are three new HPV 16 E6 inhibitors that were created utilizing a fragment-based methodology. The trials subset in the ZINC database was screened virtually using the structural information of these three novel chemicals, yielding 9800 hits. Using the GLIDE module of the Schrodinger software, three virtual screening phases were applied to the molecules that were collected from the database. MD simulations and DFT (Density Function Theory) were also carried out.

RESULTS

The findings indicated that when compared to the reference molecule, luteolin, the five-hit compounds (ZINC000034853956, ZINC000001534965, ZINC000095617673, ZINC000005764481, and ZINC000071606215) demonstrated superior glide scores. Important interactions between these compounds and the HPV 16 E6 protein were seen. Using the QikProp tool, the pharmacokinetic characteristics of these hit compounds were examined. The findings demonstrated that the pharmacokinetic characteristics and oral absorption by humans of all five compounds were found to be satisfactory. Except for ZINC000005764481, all five hit compounds were predicted to be toxic; the remaining four displayed drug-like characteristics.

CONCLUSION

To create HPV 16 E6 inhibitors for the treatment of HPV-related disorders, the four hit compounds (ZINC000034853956, ZINC000001534965, ZINC000095617673, and ZINC00007160- 6215) can be employed as lead molecules.

摘要

背景

人乳头瘤病毒(HPV)感染是最常见的性传播疾病之一。目前的治疗方法包括使用化疗药物或通过手术切除已形成的肿瘤。随着基于药物的治疗方法的出现,出现了一种更经济实惠的治疗HPV相关疾病的选择。E6蛋白与E6相关蛋白(E6AP)之间的相互作用在HPV感染的细胞中产生p53降解复合物,这促进了癌症的发生。

目的

本研究旨在使用虚拟筛选技术寻找针对HPV16 E6蛋白的潜在小分子抑制剂。

方法

化合物5、7和10是利用基于片段的方法设计的三种新型HPV 16 E6抑制剂。利用这三种新型化合物的结构信息对ZINC数据库中的试验子集进行虚拟筛选,得到9800个命中化合物。使用薛定谔软件的GLIDE模块对从数据库中收集的分子进行三个虚拟筛选阶段。还进行了分子动力学(MD)模拟和密度泛函理论(DFT)计算。

结果

结果表明,与参考分子木犀草素相比,五个命中化合物(ZINC000034853956、ZINC000001534965、ZINC000095617673、ZINC000005764481和ZINC000071606215)表现出更好的Glide评分。观察到这些化合物与HPV 16 E6蛋白之间存在重要的相互作用。使用QikProp工具检查这些命中化合物的药代动力学特征。结果表明,所有五种化合物的药代动力学特征和人体口服吸收情况均令人满意。除ZINC000005764481外,所有五种命中化合物预计均有毒性;其余四种显示出类药物特性。

结论

为了开发用于治疗HPV相关疾病的HPV 16 E6抑制剂,这四种命中化合物(ZINC000034853956、ZINC000001534965、ZINC000095617673和ZINC000071606215)可作为先导分子。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验